Drugs / DTaP-IPV combination vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02458183 | Feb 2015 → Dec 2017 | diphtheria, pertussis, poliomyelitis, tetanus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV combination vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02458183 ↗ |
| Known as | DTaP-IPV | “A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular...” NCT02458183 ↗ |
| Modality | Vaccine | “DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine” NCT02458183 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT02458183 ↗ |